Skip to main content
IRS-authorized e-file provider · not the IRS

Nonprofit · EIN 74-1541767

CLAYTON FOUNDATION FOR RESEARCH

Tax-exempt · HOUSTON, TX 77056

Financials

$11M$10.8M2023$14.9M$10.9M2024
Revenue Expenses · by fiscal year end
Financials of CLAYTON FOUNDATION FOR RESEARCH by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2024990$14,857,333$10,938,202$3,919,131$144,353,789$6,584,095$137,769,694
December 31, 2023990$11,043,790$10,750,530$293,260$130,572,468$7,121,038$123,451,430
Financial details: 990 for the year ended December 31, 2024

Revenue

Contributions, gifts and grants
$2,025,000
Program service revenue
$0
Investment income
$12,739,333
Royalties
$93,000
Net gain from sales of assets
$10,333,834
Other revenue
$93,000

Expenses

Grants and similar amounts paid
$51,500
Compensation of officers, directors and key employees
$1,666,825
Other salaries and wages
$2,825,950
Salaries, compensation and benefits (total)
$6,744,599
Professional fundraising fees
$0
Legal fees
$22,306
Accounting fees
$53,757
Travel
$39,534
Depreciation
$398,768
Program services (functional)
$9,071,928
Management and general (functional)
$1,866,274

Balance sheet and other

Total assets, start of year
$130,572,468
Total assets, end of year
$144,353,789
Total liabilities, end of year
$6,584,095
Net assets, end of year
$137,769,694
Land, buildings and equipment
$2,145,487
Publicly traded securities
$102,655,928
Net assets without donor restrictions
$97,145,314
Net assets with donor restrictions
$40,624,380
Gross receipts
$15,895,618
Employees
53
Year formed
1965
State of legal domicile
TX

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2024, highest compensation first.

NameTitleHours / weekCompensationFrom related orgsOther / benefits
Jarred W SloanTrustee, President, Treasurer
Trustee or director, Officer
20$283,402$402,613$99,413
Robert M WallaceTrustee, Vice President
Trustee or director, Officer
20$210,286$475,729$99,413
Lynn P CarterTrustee
Trustee or director
8$100,624$585,391$99,413
Joan S DunlapTrustee VP, Secretary
Trustee or director, Officer
4$159,140$458,605$89,294
Brian W CrozierTrustee, Chairman
Trustee or director, Officer
5$100,624$256,424$49,850
Robert L EvansVP, Assistant Treasurer
Officer
40$222,000$0$83,150
Kimberly A ShipleyAssistant Secretary
Officer
40$178,200$0$76,580
Lawrence H CheungProject Researcher40$114,406$0$40,030
990 for the year ended December 31, 2023: 9 people
NameTitleHours / weekCompensationFrom related orgsOther / benefits
Jarred W SloanTrustee, President, Treasurer
Trustee or director, Officer
20$274,083$389,373$97,800
Robert M WallaceTrustee, Vice President
Trustee or director, Officer
20$203,370$460,086$97,800
Lynn P CarterTrustee
Trustee or director
8$97,315$566,141$97,800
Joan S DunlapTrustee, VP, Secretary
Trustee or director, Officer
4$126,473$373,613$88,019
Brian W CrozierTrustee, Chairman
Trustee or director, Officer
5$97,315$247,991$50,086
Thomas J BrorbyTrustee, Deceased
Trustee or director, Officer
5$80,872$206,090$16,600
Robert L EvansVP, Assistant Treasurer
Officer
40$210,000$0$81,846
Kimberly A ShipleyAssistant Secretary
Officer
40$173,267$0$76,336
Lawrence H CheungProject Researcher40$114,406$0$40,035

Address and contacts

Address (IRS master file)
1 RIVERWAY STE 1500, HOUSTON, TX 77056-1950
Principal officer (990 for 2024)
Jarred W Sloan, One Riverway 1500, Houston, TX 77056
Signed the 990
Jarred W Sloan, President
Phone
(713) 817-5259

Mission

The primary mission is to conduct medical research in conjunction with hospitals for the purpose of discovering the cause, prevention and cure of diseases for the benefit of mankind. The secondary mission is to transfer the resulting medical research discoveries from the laboratory to the use of the general public by patenting and licensing such technology for development into drugs or other products for the use and benefit of mankind through the Foundation's supporting entities.

990 for the year ended December 31, 2024

Program accomplishments

  • A long standing research project at the University of Texas at Austin under the direction of Dr. Brent Iverson is in the field of engineering proteases. One aim of the project is to discover engineered proteases that will serve as more efficient, next generation antibody replacements. The engineered proteases will cleave the protein disease target in a catalytic fashion, thus requiring much less drug and enabling far lower doses and potentially fewer side effects. This project has resulted in the generation of a technology platform to support the development of protease therapeutics called Yeast Endoplasmic Reticulum Sequestration Screening (YESS). In addition to protease engineering, this platform is generating valuable information on enzyme substrate profiling. This allows to profile resistance in kinase inhibitor drugs and to generate kinase inhibitors and protease inhibitors with very low resistance and much higher specificity. This platform has been validated, and lead small drug candidates are currently being developed. Several publications have created interest in the scientific community in the YESS platform. Patent applications have been filed by RDF, one of the Foundation?s supporting entities, on several discoveries arising out of this research.
    Expenses $1,030,206
  • A research project at Baylor College of Medicine in gene and protein therapy focuses on inappropriate cell division and cell death within the human body. Much of the work is devoted to intraocular angiogenesis, with particular attention to: (1) the signals that control this process, (2) the development of animal models of human ocular disease, and (3) development of potential therapies. New targets have been identified and potential therapeutic agents are being developed and tested for the treatment of wet AMD, Diabetic Retinopathy, and Retinopathy of Prematurity.
    Expenses $964,510
  • The conduct of a longstanding research program at the University of Texas M. D. Anderson Cancer Center(which program moved to Texas A&M Institute of Biosciences and and Technology during the year) , the purpose of which is to design and develop novel targeted therapeutic agents that target a powerful human toxin to specifically destroy cancer cells for the treatment of numerous cancer targets and other disease indications. A number of collaborations have been undertaken with researchers at various institutions (e.g., University of California San Diego). Patent applications have been filed by Research Development Foundation (RDF), a tax exempt supporting organization of the Foundation (see schedule R, Part III), on more than twenty discoveries, and a number of patents have been issued. Licensing efforts have been ongoing and have resulted in several licenses.
    Expenses $910,134
  • Vaccines, Diagnostics and Therapeutics for the Ehrlichioses at The Univerity of Texas Medical Branch at Galveston
    Expenses $825,546
  • Development of Biorepository and Novel Therapeutic Strategies for Hepatocellular Carcinoma at the University of Texas Health Science Center at San Antonio
    Expenses $807,116
  • Early Detection and Treatment of Glaucoma Baylor College of Medicine Houston
    Expenses $674,935
  • Identification of Host-based Antiviral Targets at the University of Texas Southwestern Medical Center Dallas
    Expenses $637,144
  • The Use of Light for Cardiological, Surgical, and Related Purposes at the University of Texas Health Science Center at San Antonio
    Expenses $622,259
  • Antibody Discovery and Optimization Using the Eclonal Technology at The University of Texas at Austin
    Expenses $589,586
  • Electroceutical Sciences and Medicine at Dell Medical School at the University of Texas
    Expenses $495,150
  • Developing Drug Delivery Systems for Testing Solid Tumors at Dell Medical School at the University of Texas
    Expenses $491,527
  • Discovering New Mechanisms and Therapeutics for Brain Injury at the University of Texas Southwestern Medical Center Dallas
    Expenses $425,701
  • Development of Artificial Neurotransmitter Systems at the University of Texas at Austin
    Expenses $361,410
  • Optimization and Charactorization of AAV for Gene Therapy at Dell Medical School at The University of Texas
    Expenses $236,704
  • Grants
    grants $51,500

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026Not on file
2024December 31, 2024May 15, 2025990 on file
2023December 31, 2023May 15, 2024990 on file

IRS record

EIN
74-1541767
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Hospital or medical research organization
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
1966
Accounting year ends
December
Files
Form 990 or 990-EZ
Assets (IRS master file)
$144,353,789
Income (IRS master file)
$15,895,618

Filing history

FormYear endedRevenueExpensesAssetsReturn
990December 2024$14,857,333$10,938,202$144,353,789XML
990December 2023$11,043,790$10,750,530$130,572,468XML
990December 2022$6,604,622$10,006,620$112,685,763IRS
990December 2021–––IRS
990December 2020–––IRS

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 74-1541767).

Questions about CLAYTON FOUNDATION FOR RESEARCH

What is the EIN of CLAYTON FOUNDATION FOR RESEARCH?
The employer identification number (EIN) of CLAYTON FOUNDATION FOR RESEARCH is 74-1541767.
Is CLAYTON FOUNDATION FOR RESEARCH tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1966.
Are donations to CLAYTON FOUNDATION FOR RESEARCH tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does CLAYTON FOUNDATION FOR RESEARCH file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of CLAYTON FOUNDATION FOR RESEARCH due?
The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
When did CLAYTON FOUNDATION FOR RESEARCH last file with the IRS?
The latest return in the IRS public files is the 990 for the year ended December 2024.
Who is the principal officer of CLAYTON FOUNDATION FOR RESEARCH?
The 990 for the year ended December 31, 2024 names Jarred W Sloan.
Who are the officers and directors of CLAYTON FOUNDATION FOR RESEARCH?
The 990 for the year ended December 31, 2024 lists 8 people; 8 received compensation from the organization, the highest $283,402 (Jarred W Sloan, Trustee, President, Treasurer).
How much revenue does CLAYTON FOUNDATION FOR RESEARCH have?
On its 990 for the year ended December 31, 2024 it reported revenue of $14,857,333, expenses of $10,938,202 and total assets of $144,353,789 at year end.

Other nonprofits in HOUSTON

All nonprofits in HOUSTON · Texas · Medical research